Long acting GLP-1 receptor agonist (injectable)
Efpe sc
EFPE_SC
Doses in this pooled treatment
- Efpe sc 1mg qw
- Efpeglenatide 2 mg subcutaneous once weekly
- Efpeglenatide 4 mg subcutaneous once weekly
- Efpe sc 8mg qm
- Efpe sc 12mg qm
- Efpeglenatide 16 mg injection monthly
- Efpeglenatide 8 mg injection every 4 weeks
- Efpeglenatide 12 mg injection every 4 weeks
- Efpeglenatide 16 mg injection every 4 weeks
- Efpeglenatide 6 mg subcutaneous once weekly
- Efpeglenatide 6 mg injection every 2 weeks
- Efpeglenatide 8 mg injection every 2 weeks
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.62 (-2.81 to 1.54) | 0.43 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.84 (-1.91 to 0.35) | 0.42 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.37 (-6.08 to 3.58) | 0.55 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.44 (-6.48 to 3.62) | 0.84 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 4.99 (0.83 to 24.53) | 0.36 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 3.93 (0.90 to 13.50) | 0.47 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.36 (0.05 to 54.49) | 0.26 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.38 (0.00 to 23.41) | 0.76 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 2.35 (0.16 to 70.68) | 0.40 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.92 (0.46 to 1.94) | 0.54 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.34 (1.39 to 8.80) | 0.22 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 11.74 (4.09 to 41.74) | 0.05 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 8.98 (2.74 to 42.44) | 0.13 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.13 (1.13 to 4.25) | 0.31 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.25 (0.96 to 5.93) | 0.31 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.90 (1.06 to 19.46) | 0.27 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.83 (0.09 to 8.84) | 0.39 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -3.13 (-12.07 to 6.16) | 0.47 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -6.81 (-14.60 to 0.97) | 0.54 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 21.85 (4.99 to 105) | 0.78 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 11.56 (2.04 to 89.44) | 0.61 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.34 (0.56 to 137) | 0.22 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.10 (0.69 to 7.50) | 0.52 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.94 (2.08 to 8.17) | 0.44 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.79 (1.32 to 13.14) | 0.57 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.25 (0.56 to 2.94) | 0.68 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.30 (0.81 to 7.42) | 0.44 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 5.27 (1.07 to 48.14) | 0.28 |
Trials
- AMPLITUDE-MA 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise2017 · 406 randomized · 56 weeks
- NCT02081118A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin2014 · 209 randomized · 16 weeks
- NCT02075281A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes2014 · 297 randomized · 20 weeks
- NCT02059564A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus2013 · 47 randomized · 13 weeks